APPLICATION OF PK MODELLING FOR RIVAROXABAN Sample Clauses

APPLICATION OF PK MODELLING FOR RIVAROXABAN. The pharmacokinetics of rivaroxaban describes the time course of its concentration in vivo. Studies using high performance liquid chromatography-tandem mass spectrometry to measure rivaroxaban concentration, have been used to calculate the pharmacokinetics of rivaroxaban. (Xxxxxxx et al., 2008; Xxxxxxx et al., 2013) PPK plays a crucial role in developing dosing strategies for drug development and providing detailed information for a target patient group. The specific covariate impacting on the drug in question can then be identified. The advantage of PPK method is that sparse data collection can be used to calculate PK parameters for the drug in question. The pharmacodynamics of rivaroxaban, which illustrates the relationship between rivaroxaban dose and effect, is less comprehensively understood, due to both the complexity of the coagulation system in vivo and the limitations of the current laboratory tools for measuring this. Post-marketing research is essential to enable a full understanding of the effectiveness of rivaroxaban, its potential for adverse effects and how quickly and long- lasting the beneficial and adverse effects may be. Inferences on how the pharmacokinetics (PK) of a drug determine its pharmacodynamics (PD), as measured in individuals, can be made using PK-PD population modelling. Pharmacokinetic and pharmacodynamic (PK-PD) modelling for rivaroxaban characterise the PK parameters of rivaroxaban and links them to its PD activity in a conceptual framework model. PK-PD population modelling is the application of this PK-PD model to a general population for describing data, derived from more than one individual, by borrowing information between individuals to fill in gaps in the PK-PD profiles of each individual. Crucially, rivaroxaban is prescribed as a fixed dose for all patients, with a few exceptions. It is accepted that every individual has a specific response to any drug, which is characterised by predictable and unpredictable PK outcomes. In order to maximise an individual’s response to a drug, the PK profiling must be described as comprehensively as possible, identifying as many covariates and unpredictable inter-individual variables as possible, termed co-variants. A set of statistical techniques is applied, enabling understanding of the typical response in a population and the variability in that response which arises from various factors. PK population modelling is an important tool to integrate data and knowledge, enabling quant...
Sample 1

Related to APPLICATION OF PK MODELLING FOR RIVAROXABAN

  • Variation of order of application The Agent may, with the authorisation of the Majority Lenders and the Swap Bank, by notice to the Borrowers, the Security Parties and the other Creditor Parties provide for a different manner of application from that set out in Clause 17.1 either as regards a specified sum or sums or as regards sums in a specified category or categories.

  • Notice of variation of order of application The Agent may give notices under Clause 17.2 from time to time; and such a notice may be stated to apply not only to sums which may be received or recovered in the future, but also to any sum which has been received or recovered on or after the third Business Day before the date on which the notice is served.

  • Recognition of U.S. Special Resolution Regimes (a) In the event a Covered Party becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer of this Agreement (and any interest and obligation in or under, and any property securing, this Agreement) from such Covered Party will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement (and any interest and obligation in or under, and any property securing, this Agreement) were governed by the laws of the United States of America or a State of the United States of America. (b) In the event that a Covered Party or any BHC Affiliate of such Covered Party becomes subject to a proceeding under a U.S. Special Resolution Regime, any Default Right under this Agreement that may be exercised against such Covered Party is permitted to be exercised to no greater extent than such Default Right could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States of America or a State of the United States of America.

  • LIABILITY FOR UNAUTHORIZED USE-LOST/STOLEN CARD NOTIFICATION You agree to notify Credit Union immediately, orally or in writing at Florida Credit Union, X.X. Xxx 0000, Xxxxxxxxxxx, XX 00000 or telephone (000) 000-0000 twenty four

  • Public Posting of Approved Users’ Research Use Statement The PI agrees that information about themselves and the approved research use will be posted publicly on the dbGaP website. The information includes the PI’s name and Requester, project name, Research Use Statement, and a Non-Technical Summary of the Research Use Statement. In addition, and if applicable, this information may include the Cloud Computing Use Statement and name of the CSP or PCS. Citations of publications resulting from the use of controlled-access datasets obtained through this DAR may also be posted on the dbGaP website.

  • New Application for Licensure Any time after the three-month period has lapsed from the Effective Date of this Agreement and Respondent has paid the Administrative Penalty set forth in Section III, Paragraph 1 of this Order, Respondent may apply for a new mortgage loan originator license or, as applicable, petition for the reinstatement of an MLO Activity Endorsement in any or all of the Participating States with the understanding that each State Mortgage Regulator reserves the rights to fully investigate such application for licensure or petition for reinstatement of an MLO Activity Endorsement and may either approve or deny such application or petition pursuant to the normal process for such licensing or endorsement investigations. No license application or petition described in this paragraph will be denied solely based on the facts, circumstances, or consensual resolution provided for in this Agreement. Respondent further agrees that Respondent must satisfy the Administrative Penalty provision prior to submitting an application for a new mortgage loan originator license or, as applicable, petition for the reinstatement of an MLO Activity Endorsement.

  • Application of Agreement 4.1 This Agreement applies to: (a) Xxxxx Fabrications Pty Ltd (the Employer) (b) the CFMEU (the Union) (c) all Employees of the Employer engaged in construction work and for whom classifications and rates of pay are provided by this Agreement (the Employee). Collectively known as Parties 4.2 This Agreement only applies to work done in Queensland or Northern Territory and to work temporarily done outside Queensland or Northern Territory by Employees who are based in Queensland or Northern Territory, except where employees are covered by a subsequent Greenfields agreement made under s.182(3) of the Fair Work Act 2009 (Cth) and approved by the Fair Work Commission.

  • Recognition of the U.S. Special Resolution Regimes (a) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. (b) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.

  • Terms of Use The Clean Energy Council Limited (CEC) owns all intellectual property rights in the Solar PV Sale and Installation Agreement (Agreement).

  • Implementation of Agreement Each Party must promptly execute all documents and do all such acts and things as is necessary or desirable to implement and give full effect to the provisions of this Agreement.